Germany's BioNTech plans UK trial of mRNA cancer therapy

Germany's BioNTech plans UK trial of mRNA cancer therapy

Scientists believe mRNA vaccines could be a game-changer against many diseases
Scientists believe mRNA vaccines could be a game-changer against many diseases. Photo: Daniel ROLAND / AFP/File
Source: AFP

German pharmaceutical company BioNTech, which developed a trailblazing Covid-19 vaccine, will trial a cancer treatment in Britain using the same mRNA technology, the company said on Friday.

Up to 10,000 people will receive the immunotherapy tailored to individual tumours by the end of 2030, either in trials or as an approved treatment, BioNTech said in a statement.

The project is part of a new agreement with the British government focused on "cancer immunotherapies, infectious disease vaccines, and expansion of BioNTech's footprint in the UK", the company said.

BioNTech will also open a new research and development centre with around 70 staff in Cambridge, as well as setting up a regional headquarters in London.

"Our goal is to accelerate the development of immunotherapies and vaccines using technologies we have been researching for over 20 years," said Ugur Sahin, CEO and co-founder of BioNTech.

Read also

UK drops contentious plan to privatise TV network

The UK "successfully delivered Covid-19 vaccines so quickly", he said, demonstrating "that drug development can be accelerated without cutting corners if everyone works seamlessly together towards the same goal".

PAY ATTENTION: Join Legit.ng Telegram channel! Never miss important updates!

The messenger RNA method made its debut with the Pfizer/BioNTech coronavirus vaccine, which was the first jab against Covid to be approved in the West in late 2020.

Scientists believe mRNA vaccines, which provoke an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells, could be a game-changer against many diseases.

They also take less time to develop than traditional vaccines.

BioNTech's Covid-19 shot was developed and approved by regulators in less than a year.

BioNTech is also working on mRNA-based vaccines against malaria, influenza and shingles.

The company has been developing mRNA-based cancer therapies since it was founded in 2008 and they have been trialled on several hundred people so far.

Source: AFP

Authors:
AFP avatar

AFP AFP text, photo, graphic, audio or video material shall not be published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP news material may not be stored in whole or in part in a computer or otherwise except for personal and non-commercial use. AFP will not be held liable for any delays, inaccuracies, errors or omissions in any AFP news material or in transmission or delivery of all or any part thereof or for any damages whatsoever. As a newswire service, AFP does not obtain releases from subjects, individuals, groups or entities contained in its photographs, videos, graphics or quoted in its texts. Further, no clearance is obtained from the owners of any trademarks or copyrighted materials whose marks and materials are included in AFP material. Therefore you will be solely responsible for obtaining any and all necessary releases from whatever individuals and/or entities necessary for any uses of AFP material.